

1 **Effectiveness of the air-filled technique to reduce the dead space**
2 **in syringes and needles during ChAdox1-n CoV vaccine administration**

3
4
5 ¶ Patchara Phankavong^{1*}, ¶ Naphatthorn Prueksaanantakal², ¶ Nontawat Benjakul¹, ¶ Anan
6 Manomaipiboon¹

7
8
9 ¹Faculty of Medicine, Vajira Hospital, Navamindradhiraj University

10 ²Kuakarun Faculty of Nursing, Navamindradhiraj University

11
12 Short Title: Air-Filled Technique for ChAdox1-n CoV Vaccine Administration

13
14 Corresponding Author:

15 Email: patchara@nmu.ac.th

16 ¶ These authors contributed equally to this work.
17
18
19
20
21
22
23
24
25
26
27
28
29

32 **Abstract**

33 In the current study, we calculated the vaccine volume and amount of dead space in a
34 syringe and needle during ChAdox1-n CoV vaccine administration using the air-filled technique, to
35 reduce dead space in syringe and needle that administer up to 12 doses per vial. The hypothetical
36 situation uses a vial with a similar size as the ChAdox1-n CoV vial. We used distilled water (6.5 ml),
37 to fill the same volume as five vials of ChAdox1-n CoV. When 0.48 ml of distilled water is drawn
38 according to the number on the side of the barrel, an additional 0.10 ml of air can be used in the dead
39 space of the distilled water in the syringe and needle for 60 doses, which can be divided into an
40 average of 0.5 ml dose. ChAdox1-n CoV was administered using a 1-mL syringe and 25G needle to
41 administer ChAdox1-n CoV vaccine into 12 doses using this air-filled technique. The volume of the
42 recipient vaccine will be increase by 20% and save the budget of a low dead space syringe (LDS).

43 Keywords: Air-filled technique, ChAdox1-n CoV vaccine, COVID-19, Low dead space
44 syringe,

45

46

47

48

49

50

51

52

53

54

55

56

57

58 **Graphical Abstract**

59

60

61

62

63

64

65

66

67

68

69

70


71

72

73

74

75



77 **Introduction**

78 Since December 2019, the SARS-CoV-2 virus epidemic has spread worldwide, leading to
79 the declaration of a pandemic in March 2021[1]. Several countries have endeavored to experiment
80 and create vaccines to prevent and control the transmission of COVID-19 [2]. The main vaccines in
81 Thailand is ChAdox1-n.CoV, which has been approved by the Ministry of Public Health and the
82 Food and Drug Administration. This vaccine was registered on January 20, 2021. However, the
83 limited capacity and vaccination demand of every country has increased beyond supply, creating a
84 shortage of vaccines in most countries, including Thailand.

85 ChAdox1-n.CoV is used to enhance immunity among people ≥ 18 years of age to prevent
86 symptoms of COVID-19 [3]. This vaccine is a monovalent vaccine consisting of adenovirus from
87 chimpanzees (ChAdOx1) encrypted by the glycoprotein S of SARS-CoV-2 [4]. After injection, the
88 glycoprotein S of SARS-CoV-2 strengthens the immune system and prepares them for later
89 infection.

90 A vial of ChAdox1-n.CoV can be divided into ten doses (multiple doses) of 5 ml for ten
91 people. The manufacturers generally overfill the vial to replace the dead space in the syringe and
92 needle in the preparation and injection procedure for ten people. The amount of overfilled vaccine is
93 the same in every brand for multiple dose vials, including Pfizer, which has sufficient vaccines for
94 six people. Therefore, in many countries that have reserved COVID-19 vaccines, the multiple dose
95 type is assigned to use an low dead space (LDS) syringes and needles to reduce the wasted volume
96 that remains in the tip of the syringes and needles [5]. However, the LDS and needle cost is 4 to 10
97 times more than a 1-ml syringe and 25G needle (1 to 1.5-inch length).Therefore the latter syringes
98 and needle needles are commonly used. Additionally, no manufacturers for LDS and needles are
99 available in Thailand, and they need to be imported from overseas. Moreover, there is a worldwide
100 shortage of vaccines. Therefore, a study about vaccine administration, including the preparation and
101 injection procedure of ChAdox1-n.CoV, to allow the vaccine to be divided to 12 doses per vial

102 instead of 10, as limited by the manufacturer, is required. This procedure will help clinics suitably
103 administer the vaccine in the most efficient manner, which will mitigate the supply issues and
104 unavailability of LDS needles in many countries [6].

105

106 **Materials and Methods**

107 This research was approved by the Ethics Committee at our hospital, registration no.
108 096/2564. All procedures were performed after written informed consent from all participants.

109 The research procedure was as follows:

110 • The test was first performed using distilled water to test the hypothetical situation.

111 • A vial with a similar size as the ChAdox1-n CoV vial was used. Distilled water of the
112 same volume as a single vial of ChAdox1-n CoV (6.5 ml) was filled in the vial.

113 • A digital precision balance weighing scale was prepared to measure empty syringes and
114 vaccine (in mg) up to four decimal places and pass the calibration of National Institute of Metrology
115 Thailand (NIMT) as described below.

116 Step 1: 60 sets of 1-ml syringe and 25G needle were weighed and recorded, with a length of
117 1 inch needle, and the weighted average was calculated.

118 Step 2: 0.45 ml water with 0.1 ml air was aspirated, resulting in < 0.5 ml water being
119 ejected from the syringe.

120 Step 3: 0.48 ml of distilled water and an additional 0.10 ml of air was drawn into the syringe
121 to reduce the dead space in the syringe and needle. The amount of the water appeared to be slightly
122 more than 0.5 ml. Thereafter, the weight of 60 sets of syringe and needle were recorded and
123 weighted average was calculated.

124 Step 4: 0.5 ml of distilled water from the barrel was discarded, syringe and needle were
125 weighed, the weight recorded, and the weighted average calculated.

126 • The experiment using the same procedures was repeated until 12 doses of distilled water
127 were obtained per vial, for which the amount in every dose was ≥ 0.5 ml.

128 • The second stage involved using ChAdox1-n CoV in the real situation in the same way as
129 in the hypothetical situation as described below.

130 Step 1: Sixty sets of 1-ml syringes and 25G needles, with a length of 1 inch needle, were
131 weighed, the weight recorded, and the weighted average calculated. Five vials of vaccine were used.
132 Because a vial can be divided into 12 doses, five vials would comprise 60 doses.

133 Step 2: The vaccine was prepared by stabbing the needle in the vaccine vial and drawing in 0.48
134 ml of vaccine and an additional 0.10 ml of air to reduce the dead space in the syringe and needle.
135 The amount of the vaccine would appear to be equal to or slightly more than 0.5 ml. Thereafter, the
136 60 syringe and needle sets were weighed, the weight recorded, and the weighted average calculated.

137 Step 3: The vaccine was injected to the muscle of the vaccine recipient following the
138 vaccine administration instructions composed by the Nursing Department of the Faculty of Medicine,
139 Vajira Hospital, Navamindradhiraj University. Thereafter, the 60 syringe and needle sets were
140 weighed, the weight recorded, and the weighted average calculated.

141 **ChAdox1-n CoV Injection Technique**

142 The vaccine injection using the same needles to draw vaccine from the same vial could
143 allow the diseases to spread easily, such as Hepatitis B, Hepatitis C, and human immunodeficiency
144 virus (HIV). Thus, the hospital and universal infectious control guidance precautions were strictly
145 adhered to the aseptic technique. The vaccine injection procedures are described below.

146 1. Medical personnel must wear a surgical mask, glasses, and face shield, and sanitize their
147 hands with hand sanitizer and wear suitable gloves.

148 2. The medical personnel and recipients receiving injection must be explained to put one of
149 their upper arms on the table or on the surface, which is not higher than shoulder level, and not flex their
150 shoulder and upper arm muscles during the injection.

151 3. The syringe should be checked if it contains is 0.5 ml of the vaccine as prescribed by Astra
152 Zeneca. The skin where the vaccine is to be injected is cleaned with 70% alcohol and left to dry.

153 4. Before injecting the vaccine, the syringe should be pointed at 90 degrees to let the air
154 flow to the top of the barrel. Flicking the finger lightly on the barrel helps the air bubble move to the
155 top (the syringe should not be shaken). Next, needle should be inserted through the subcutaneous
156 layer to the muscle ensuring that the tip of the needle is not in the blood vessel, and inject the vaccine
157 by pushing the plunger to the end. The air on the top part of the syringe pushes the dead space in the
158 syringe and needle to the muscle by a slight amount. Therefore, less than 1 mL air might pass to the
159 muscle, which does not cause any harm. If the medical personnel and recipients receiving injection
160 have a thick subcutaneous layer, a 1.5-length 25G needle should be used instead.

161 5. the needle should be pulled out from the vaccine recipient and removed in the needle
162 clipping devices without using the luer lock. The syringe and all other equipment used should be
163 discarded in the infectious waste disposal container.

164 6. Finally a band-aid should be placed on the injection wound and the vaccine recipient
165 should be asked to wait in the waiting area to observe whether any symptoms occur after the
166 injection.

167 The researcher should check the specific gravity in the five vials of the ChAdox1-n CoV
168 used in the experiment to calculate the volume that the patient has received.

169

170 **Statistical Analysis**

171 The data was analyzed using SPSS Program, Version 28 (Chulalongkorn University
172 Bangkok Thailand) to calculate the weighted average of the syringe, needle, vaccine, volume, and
173 standard variation.

174

175

176

177

178 **Results**

179 In the experiment using 6.5 ml of the distilled water in the vial, having the same size as the
180 ChAdox1-n CoV vial, 0.48 ml of distilled water and an additional 0.1 ml of air to replace the dead
181 space of the distilled water in the syringe and needle was drawn. The distilled water was
182 administered to 12 doses per vial. The weighted average in the syringe before injecting was
183 evaluated to be 0.5168 ml, the weighted average of dead space 0.0122 ml, and the volume of distilled
184 water injected out of the syringe 0.5046 ml.

185 The ChAdox1-n CoV vaccine administration experiment used a normal syringe and needle
186 to draw in 0.48 ml of the vaccine, according to the number on the side of the barrel and an additional
187 0.10 ml of air to reduce the dead space in the syringe and needle. We then used this procedure to
188 prepare 0.5 mL or slightly more of ChAdox1-n CoV vaccine using a 1-ml syringe and 25G needle to
189 draw in the 0.48 ml of the vaccine, according to the number on the side of the barrel, and an
190 additional 0.10 ml of air to reduce the dead space in the syringe and needle x. We could administer
191 12 doses per vial. The weighted average of the vaccine before injecting was found to be 0.5048 ml
192 and the weighted average of the dead space 0.0263 ml. Thus, the volume of the vaccine that the
193 recipient would receive was 0.5048 ml (the weight of the vaccine that the recipient would receive
194 was = $0.5199/1.030$ [sp.gr. of the vaccine])

195

196 **Discussion**

197 This experiment was aligned with research on antibody level for SARS-CoV-2 after
198 injection of the 1st dose of ChAdox1- n CoV-19 using 12 doses per vial [8]. We found that
199 approximately 8.57 weeks after injecting 12 doses per vial, the level of immunity was higher at a
200 positive value of 93.3%, and higher among women than men. Additionally, the immunity did not

201 vary according to age, disease, body mass index, blood type, and blood pressure, and corresponded
202 with the advice from the Pfizer-BioNTech COVID-19 Vaccine, which uses LDS to divide six doses
203 of vaccine per vial. After injecting the vaccine to the recipient, we found ≤ 0.035 ml dead space in the
204 syringe. From this experiment using the air-filled technique to reduce the dead space in the syringe
205 and needle, 0.0263 ml of the vaccine remained. Thus, the vaccine recipient will receive 0.5048 mL
206 volume of the vaccine using the 1-ml syringe and 25G needle instead of the LDS. This technique will
207 reduce the expenses of importing LDS, which costs 2.78 THB per syringe compared to 1.65 THB for
208 a 1 ml syringe and 0.43 THB for a 25G needle. This administrative technique increases the amount
209 of the recipient vaccine by 20% and is more economized than using LDS. This will help the Nursing
210 Department of the Faculty of Medicine, Vajira Hospital to create guidelines and strategies to
211 administer the vaccine using the air-filled technique to reduce the dead space in the syringe and
212 needle, as well as to publish an interdisciplinary method in vaccine administration for all vaccine
213 recipients.

214

215 **Conclusion**

216 ChAdox1-n CoV vaccine administration using a 1-ml syringe and 25G needle to draw in
217 0.48 ml of vaccine, according to the number on the side of the barrel, and an additional 0.10 ml air,
218 to reduce the dead space in the syringe and needle, to achieve an average volume of 0.5 ml (or
219 slightly more), allowed the vaccine to be administered at 12 doses per vial. The air-filled and vertical
220 injection techniques included flicking the finger lightly on the barrel to let the air flow to the top of
221 the barrel. Then, the syringe was pointed at 90 degrees to pierce the muscle before pushing the
222 plunger to the end. The air on the top pushed the dead space at the tip of the syringe and needle. We
223 found that 0.0263 ml of dead space remained.

224

225

226

227

228

229 **Acknowledgment**

230 We wish to thank Assoc. Prof Anayn Manomaipiboon, the chancellor of Navamindradhiraj
231 University for providing advice and ideas relating to all aspects of this research.

232 We wish to thank Dr. Nontawat Benjakul, MD, Faculty of Medicine, Vajira Hospital in
233 Anatomical Pathology, Navamindradhiraj University for his assistance with the writing of the
234 manuscript and for proofreading the final document.

235 We wish to thank Ms. Yupin Chalermchai, Ms. Pensiri Kaewkasikarn, Ms. Chantana
236 Jinawong, Ms. Warisa Jirawatin, and all the registered nurses and staff for their support.

237

238 **Author contributions**

239 AM conceptualized the method, designed experimental protocols and validation tests; PP
240 and NP conducted the experiments; AM and PP conducted data analysis and visualization; and PP
241 and NB wrote the manuscript.

242

243 **Ethics committee approval**

244 The experiment was performed in accordance with the principles of the Declaration of
245 Helsinki and Good Clinical Practice. This study was approved by the Vajira Institutional Review
246 Board, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University. The vaccine used was
247 authorized by the Thai FDA and the Department of Medical Science (DMS).

248

249 **Conflict of Interest Statement**

250 All the authors declare that they have no competing interests.

251

252 **Funding source**

253 This work was supported by a grant from Navamindradhiraj University

254

255 **Data availability statement**

256 All data used in the preparation of the manuscript are related to the previously published

257 article and can be found in the Mendeley Data repository: “ChAdOx1nCoV-19 vaccination,”

258 Mendeley Data, V1, doi: 10.17632/yjhssw33cw.1

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279 **References**

- 280 1. Bhattacharyya A, Seth A, Srivast N, Imeokparia M, Rai S.. Coronavirus (COVID-19): A systematic
281 review and meta-analysis to evaluate the significance of demographics and comorbidities. Res Sq. 2021; rs.
282 3.rs-144684. doi:10.21203/rs.3.rs-144684/v1
- 283 2. Chang J, Agliata J, Guarinieri M. COVID-19 - Enacting a 'new normal' for people who use drugs.
284 Int J Drug Policy. 2020;83:102832. doi:10.1016/j.drugpo.2020.102832
- 285 3. Garba B, Zakaria Z, Salihu MD, Bande F, Saidu B, Bala JA. Breaking the cycle of the COVID-19
286 transmission: A challenge for Nigeria. J Glob Health. 2020;10(2):020309.
287 doi:10.7189/jogh.10.020309
- 288 4. COVID-19 Vaccine Important Information about the AstraZeneca vaccine Vaxzevria 29 April
289 2021. Accessed on May 10 from [https://www.hse.ie/eng/services/news/newsfeatures/COVID19-](https://www.hse.ie/eng/services/news/newsfeatures/COVID19-updates/COVID-19-vaccine-materials/important-information-about-COVID19-vaccine-astrazeneca.pdf)
290 [updates/COVID-19-vaccine-materials/important-information-about-COVID19-vaccine-](https://www.hse.ie/eng/services/news/newsfeatures/COVID19-updates/COVID-19-vaccine-materials/important-information-about-COVID19-vaccine-astrazeneca.pdf)
291 [astrazeneca.pdf](https://www.hse.ie/eng/services/news/newsfeatures/COVID19-updates/COVID-19-vaccine-materials/important-information-about-COVID19-vaccine-astrazeneca.pdf)
- 292 5. Hancock E, Ward Z, Ayres R, Neale J, Hussey D, Kesten JM, et al.. Detachable low dead space
293 syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an
294 economic evaluation. Addiction. 2020;115(4):702-713. doi:10.1111/add.14849
- 295 6. Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination
296 against SARS-CoV-2: A systematic review of existing strategies and guidelines. Vaccines
297 (Basel). 2021;9(4). doi:10.3390/vaccines9040326
- 298 7. Kesten JM, Ayres R, Neale J, Clark J, Vickerman P, Hickman M, et al.. Acceptability of low dead
299 space syringes and implications for their introduction: A qualitative study in the West of England.
300 Int J Drug Policy. 2017;39:99-108. doi:10.1016/j.drugpo.2016.09.005

- 301 8. Manomaipiboon A,, Phumisantiphong U, Maneerit J et al., Immunogenicity of the ChAdOx1 nCoV-19
302 vaccine against SARS-CoV-2 with 12- dose vial: an interim analysis. *Vaccine*. 2022; 40(4): 587-593.
303 <https://doi.org/10.1016/j.vaccine.2021.12.023>